Everything below concerns peptide stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
== Research works == After completing his PhD, he returned to the Indian Institute of Science, Bangalore, India in 1949 as an assistant professor of physics. In 1952, he moved to Madras University as professor and head of the Department of Physics where he continued his work on crystal physics. His interest, however, shifted to the structure of biological macromolecules. Using X-ray diffraction Ramachandran along with Gopinath Kartha proposed and published the triple helical structure of collagen in 1954 in the journal Nature, drawing worldwide scientific attention to the "Madras group". At Madras University, Professor Ramachandran was the favourite of the famous vice-chancellor and celebrated doctor and medical scientist, Sir Arcot Laksmanaswamy Mudaliar. Wanting to tackle problems at a more fundamental level, Ramachandran decided to use this information to examine the various polypeptide conformations then known and also to develop a good 'yardstick' that could be used for examining and assessing any structure in general, but peptides in particular. The result which emerged from these calculations in 1962, – now commonly known as the Ramachandran plot – was published in the Journal of Molecular Biology in 1963 and has become an essential tool in the field of protein conformation. When it was first calculated, crystal structures had barely been obtained for any protein.
Plasma concentrations of methadone in recovering addicts can reach 4 μM during therapy, so the actions of methadone at both the hERG potassium channel and the Nav1.5 sodium channel are possibly clinically relevant in producing cardiac side effects. This also suggests that levomethadone is not completely free of cardiac toxicity.
Space food is a type of food product created and processed for consumption by astronauts during missions to outer space. Such food has specific requirements to provide a balanced diet and adequate nutrition for individuals working in space while being easy and safe to store, prepare and consume in the equipment-filled weightless environments of crewed spacecraft. Space food is commonly freeze-dried to minimize weight and ensure long shelf life. Before eating, it is rehydrated. Unmodified food, such as items of spirulina, fruit, and even a sandwich, have been brought into space. Packaging varies, including tubes, cans, and sealed plastic packages. In recent years, space food has been used by various nations engaging in space programs as a way to share and show off their cultural identity and facilitate intercultural communication. Although astronauts consume a wide variety of foods and beverages in space, the initial idea from The Man in Space Committee of the Space Science Board in 1963 was to supply astronauts with a formula diet that would provide all the needed vitamins and nutrients.
==== Other potential disadvantages ==== Processed foods may actually take less energy to digest than whole foods, according to a study published in "Food & Nutrition Research" in 2010, meaning more of their food energy content is retained within the body. Processed foods also tend to be more allergenic than whole foods, according to a June 2004 "Current Opinion in Allergy and Clinical Immunology" article. Although the preservatives and other food additives used in many processed foods are generally recognized as safe, a few may cause problems for some individuals, including sulfites, artificial sweeteners, artificial colors and flavors, sodium nitrate, BHA and BHT, olestra, caffeine and monosodium glutamate — a flavor enhancer.
Sources: en.wikipedia.org
Antimalarial medications (like hydroxychloroquine) can inhibit chemotaxis of neutrophil and eosinophil. Calcium channel blockers can be used to relax smooth muscles and decrease the resistance of the peripheral vascular system. This can help in managing Raynaud's phenomenon.
Oxaloacetic acid + Glutamate ⇌ α-Ketoglutarate + Aspartate (catalyzed by aspartate aminotransferase) When skeletal muscle is at rest (ADP<ATP), the aspartate is no longer needed for the purine nucleotide cycle and can therefore be used with α-ketoglutarate to produce glutamate and oxaloacetic acid (the above reaction reversed).α-Ketoglutarate + Aspartate ⇌ Oxaloacetic acid + Glutamate (catalyzed by aspartate aminotransferase)
A study on the age of the carbonate thin layers covering or underlying rock art from the Cave of Altamira (Spain), providing evidence of several periods of cave art from the ceiling of the studied cave, is published by Pons-Branchu et al. (2026). Evidence from the Velika Pećina, Velika Vranovica and Pećina kod Stene cave sites (Serbia), indicative of human presence in central Balkans during the Last Glacial Maximum, is presented by Kuhn et al. (2026). Masojć et al. (2026) describe a Late Pleistocene human tooth from the Khutul Usny Cave site, representing the first fossil of an early Homo sapiens in Mongolia with secure geological context and providing evidence of presence of the species in southern Mongolia around the onset of the Last Glacial Maximum. A study on the frontal and mandibular morphology of the Red Deer Cave people, interpreted as consistent of affinities with Homo sapiens and indicative of diversity cranial morphology of late Pleistocene hominins from eastern Asia, is published by Fan et al. (2026). Evidence indicating that Solutrean artifacts from the Peña Capón rock shelter (Muriel-Tamajón, Spain) were sourced 600 to 700 kilometers away from this site, in the present-day territory of southwest France, is presented by Sánchez de la Torre et al. (2026). Nash et al. (2026) report rediscovery of putative Upper Paleolithic cave art from the Bacon Hole site (Wales, United Kingdom) originally discovered by William Sollas and Henri Breuil in 1912 and support the interpretation of the studied horizontal lines as cave art. Reiche et al.
Sources: en.wikipedia.org
The report found that AI has significant negative impacts on land, water, and climate, as it uses large amounts of electricity, requires mining of minerals, and generates large amounts of electronic waste. In 2025, data centres consumed more electricity than Saudi Arabia, and ChatGPT alone consumed an amount of water equivalent to the needs of 500,000 people in Sub-Saharan Africa. The negative impacts are not distributed equally across the planet but are concentrated in some places. Data centres are often built in places already suffering from water deficit. For example, AI deployment has already led to an increase in water scarcity in Mexico and Uruguay. It created problems with energy supply in Ireland, which forbade construction of new data centres near Dublin until 2028. Measures can involve tradeoffs, for example, transitioning from coal to bioenergy reduces carbon footprint but increases the impact on land and water. Energy efficiency might not reduce environmental impact, because as AI becomes more efficient, it also becomes cheaper and more widely used.
=== Classification === Neanderthals can be classified as a unique species as H. neanderthalensis, though some authors argue expanding the definition of H. sapiens to include other ancient humans, with combinations such as H. sapiens neanderthalensis. The latter opinion has generally been justified using Neanderthal genetics, as well as inferences on the complexity of Neanderthal behaviour based on the archaeological record. While there seems to have been some genetic contact between these two groups, there are potential indicators of hybrid incompatibility, which if true could justify species distinction. The crux of the issue lies in the vagueness of the term "species" (the species problem). Among identified archaic humans, Neanderthals are most closely related to Denisovans based on nuclear DNA (nDNA) analyses. Denisovans are an enigmatic group of Late Pleistocene humans only recognisable by a genetic signature rather than anatomical landmarks. Likely due to more recent interbreeding episodes, the mitochondrial DNA (mtDNA, passed down maternally) and Y-chromosome DNA (passed down paternally) are more similar between Neanderthals and modern humans than between Neanderthals and Denisovans. Similarly, 430,000 year old fossils from the Sima de los Huesos are more closely related to Neanderthals in their nDNA, but their mtDNA aligns more closely with Denisovans. A 2021 phylogeny of some Middle Pleistocene and Neanderthal fossils using tip dating:
=== Research and safety === G. biloba and its extracts are not approved drugs in the United States and do not have sufficient clinical evidence for uses as a therapy, according to a 2023 review. The United States National Center for Complementary and Integrative Health concludes that, despite extensive research, ginkgo has never been conclusively proven effective for any health condition, including dementia, cognitive decline, or other disorders for which it is commonly marketed. Although extracts of G. biloba leaf are often marketed to consumers as cognitive enhancers, there is no high-quality, peer-reviewed evidence supporting its use for memory or attention improvement in healthy people, as of February 2026. Systematic reviews have found no evidence for effectiveness of ginkgo extract in treating high blood pressure, menopause-related cognitive dysfunction, tinnitus, post-stroke recovery, or altitude sickness. A 2026 Cochrane review found that G. biloba shows little to no meaningful benefit for mild cognitive impairment or subjective complaints, uncertain or minimal effects in multiple sclerosis-related cognitive issues, and small to moderate, low-certainty improvements in dementia symptoms, with generally similar safety to placebo. Although a 2021 umbrella review concluded that G. biloba may be useful and safe for improving cognitive function and daily living activities in people with Alzheimer's disease, a 2023 analysis concluded there is insufficient evidence to support its use in Alzheimer's therapy. A 2016 systematic review concluded that G.
In pancreatic alpha cells, proglucagon is normally cleaved predominantly by protein convertase PC2 to generate glucagon. Under conditions of metabolic stress or beta cell injury, alpha cells can increase PC1/3 expression, resulting in alternative processing of proglucagon and production of glucagon-like peptide-1 (GLP-1) and other proglucagon-derived peptides normally associated with intestinal L-cells. Alpha cells exhibit little PC2 activity and hence produce little to no GLP-1 when healthy. In contrast, (intestinal) L-cells rely on PC1/3 to exclusively produce GLP-1 and GLP-2 from proglucagon instead of glucagon. The protein convertase switch may have protective and regenerative effect on beta cells. Another possibility is that alpha cells can potentially transdifferentiate into beta cells to replace lost beta cells.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.